Parathyroidectomy is the gold-standard treatment for brown tumours in patients with primary hyperparathyroidism, while the mainstay of treatment for secondary hyperparathyroidism in patients with dialysis-dependent chronic kidney disease is a combination of phosphate binders, active vitamin D analogs, and calcimimetics, guided by close monitoring of serum calcium, phosphate, and parathyroid hormone levels. This evidence concerns the gene PTH and secondary hyperparathyroidism.